Similar findings have been observed in human medicine, where SGLT2 inhibitors have provided consistent renal benefits, including reduction in albuminuria and slowing of estimated glomerular filtration rate decline in patients with type 2 diabetes. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.